A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and FLU HD vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 46 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 8th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 3, and was the 5th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2022.
This study's enrollment of 1,029 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 15th largest by enrollment, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 25th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Note: In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) is recommended and/or organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one dose of FLU-HD vaccine and one dose of RSVPreF3 OA vaccine, both doses administered at Day 1, and were followed until end of study.
Biological: RSVPreF3 OA investigational vaccine · Biological: FLU HD vaccine
Participants received one dose of FLU-HD vaccine at Day 1, followed by one dose of RSVPreF3 OA vaccine at Day 31, and were followed until the study end.
Biological: RSVPreF3 OA investigational vaccine · Biological: FLU HD vaccine
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).
RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)
RSV-A neutralizing titers were given as group GMTs and expressed as Estimated Dilution 60 (ED60).
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
Hemagglutinin Inhibition (HI) Titers for 4 FLU Vaccine Strains Expressed as Group GMTs
HI titers were assessed against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata strains.
Time frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)
RSV-B Neutralizing Titers Expressed as Group GMTs
RSV-B neutralizing titers were given as group GMTs and expressed as Estimated Dilution 60 (ED60).
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group)
HI Seroconversion Rate (SCR) for 4 FLU Vaccine Strains
SCR for HI titers was defined as the percentage of participants who have either a HI predose titer less than (\<) 1:10 and a post-dose titer greater than or equal to (\>=) 1:40, or a pre-dose titer \>= 1:10 and at least a 4-fold increase in post-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
Time frame: At 1 month after the FLU vaccine dose (Day 31 for both groups)
RSV-A Neutralizing Titers Expressed as Mean Geometric Increase (MGI)
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)
RSV-B Neutralizing Titers Expressed as MGI
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for the Co-Ad Group and Day 61 for the Control Group) compared to pre-vaccination (Day 1 for Co-Ad group and Day 31 for Control group)
HI Titers for Each of the 4 FLU Vaccine Strains Expressed as GMT
HI titers were assessed against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata strains. HI antibodies were expressed as GMTs, in titers.
Time frame: At Day 1 and 1 month after FLU vaccine dose administration (Day 31 for both groups)
HI Seroprotection Rate (SPR) for 4 FLU Vaccine Strains
SPR for HI titers was defined as the percentage of participants with a serum HI titer \>= 1:40. The assessed Flu strains were: The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
Time frame: At Day 1 and 1 month after FLU vaccine dose administration (Day 31 for both groups)
HI Titers for 4 FLU Vaccine Strains, Expressed as MGI
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
Time frame: At 1 month after the FLU vaccine dose administration (Day 31 for both groups)
Percentage of Participants With Solicited Administration Site Events After Each Vaccine Dose Administration
The solicited administration site events after vaccination included erythema, pain and swelling.
Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination (administered on Day 1 and 31)
Percentage of Participants Reporting Each Solicited Systemic Event After Each Vaccine Dose Administration
The solicited systemic events after vaccination include arthralgia, fatigue, fever, headache and myalgia.
Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination (administered on Day 1 and 31)
Percentage of Participants Reporting Unsolicited Adverse Events (AEs)
An unsolicited AEs is an AE that is not included in a list of solicited events using a participant diary. Unsolicited events must have been spontaneously communicated by a participant who signs the informed consent. Unsolicited AEs include both serious, non-serious AEs and potential immune-mediated diseases (pIMDs).
Time frame: Within 30 days after vaccine administration (the day of vaccination and 29 subsequent days after vaccination)
Percentage of Participants Reporting Serious Adverse Events (SAEs)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant.
Time frame: From Day 1 up to study end (6 months after last vaccination - Month 6 for Co-Ad Group and Month 7 for Control group)
Percentage of Participants Reporting Potential Immune-mediated Disease (pIMDs)
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. The investigator must exercise his/her medical/scientific judgment to determine whether other diseases have an autoimmune origin (i.e. pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and should also be recorded as a pIMD.
Time frame: From Day 1 up to study end (6 months after last vaccination - Month 6 for Co-Ad Group and Month 7 for Control group)
1029 participants received at least one dose of the study intervention and were included in the exposed set.
| Milestone | Co-Ad Group | Control Group |
|---|---|---|
| Started | 516 | 513 |
| Completed | 493 | 485 |
| Not completed | 23 | 28 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lost to follow-up | 13 | 12 |
| Withdrew: Consent withdrawal, not due to a (s)ae | 8 | 14 |
| Withdrew: Other | 0 | 2 |
RSV-A neutralizing titers were given as group GMTs and expressed as Estimated Dilution 60 (ED60).
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs) | 5876.3 (5299.5 to 6515.9) | 6935.3 (6200.0 to 7757.9) |
HI titers were assessed against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata strains.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2 | 72.7 (64.1 to 82.5) | 72.3 (63.7 to 82.1) |
| Flu A/Victoria/2570/2019 H1N1 | 189.9 (167.6 to 215.1) | 177.3 (156.4 to 200.9) |
| Flu B/Austria/1359417/2021 Victoria | 859.8 (805.8 to 917.5) | 820.9 (768.8 to 876.6) |
| Flu B/Phuket/3073/2013 Yamagata | 758.7 (699.1 to 823.4) | 703.4 (647.7 to 763.9) |
RSV-B neutralizing titers were given as group GMTs and expressed as Estimated Dilution 60 (ED60).
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| RSV-B Neutralizing Titers Expressed as Group GMTs | 8251.5 (7460.6 to 9126.3) | 8359.0 (7492.8 to 9325.3) |
SCR for HI titers was defined as the percentage of participants who have either a HI predose titer less than (\<) 1:10 and a post-dose titer greater than or equal to (\>=) 1:40, or a pre-dose titer \>= 1:10 and at least a 4-fold increase in post-dose titer. The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2 | 59.2 (54.5 to 63.8) | 57.5 (52.7 to 62.2) |
| Flu A/Victoria/2570/2019 H1N1 | 50.9 (46.2 to 55.6) | 46.8 (42.0 to 51.6) |
| Flu B/Austria/1359417/2021 Victoria | 39.7 (35.2 to 44.3) | 31.1 (26.8 to 35.7) |
| Flu B/Phuket/3073/2013 Yamagata | 43.6 (39.0 to 48.3) | 37.7 (33.2 to 42.4) |
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| RSV-A Neutralizing Titers Expressed as Mean Geometric Increase (MGI) | 5.59 (5.02 to 6.23) | 6.75 (5.93 to 7.68) |
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| RSV-B Neutralizing Titers Expressed as MGI | 5.19 (4.69 to 5.75) | 5.29 (4.65 to 6.03) |
HI titers were assessed against the Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata strains. HI antibodies were expressed as GMTs, in titers.
| Titers | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2, Day 1 | 11.5 (10.5 to 12.7) | 12.6 (11.4 to 14.0) |
| Flu A/Darwin/6/2021 H3N2, Day 31 | 71.8 (63.6 to 81.0) | 75.1 (66.7 to 84.4) |
| Flu A/Victoria/2570/2019 H1N1, Day 1 | 35.3 (31.2 to 40.1) | 41.9 (36.9 to 47.6) |
| Flu A/Victoria/2570/2019 H1N1, Day 31 | 200.0 (178.7 to 223.8) | 194.7 (173.9 to 217.9) |
| Flu B/Austria/1359417/2021 Victoria, Day 1 | 292.6 (270.6 to 316.4) | 308.5 (285.8 to 333.1) |
| Flu B/Austria/1359417/2021 Victoria, Day 31 | 848.0 (799.7 to 899.2) | 818.3 (769.2 to 870.5) |
| Flu B/Phuket/3073/2013 Yamagata, Day 1 | 239.2 (220.6 to 259.3) | 245.5 (226.1 to 266.5) |
| Flu B/Phuket/3073/2013 Yamagata, Day 31 | 751.1 (698.9 to 807.2) | 699.6 (646.9 to 756.6) |
SPR for HI titers was defined as the percentage of participants with a serum HI titer \>= 1:40. The assessed Flu strains were: The assessed Flu strains were: Flu A/Darwin/6/2021 H3N2, Flu A/Victoria/2570/2019 H1N1, Flu B/Austria/1359417/2021 Victoria, and Flu B/Phuket/3073/2013 Yamagata.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2, Day 1 | 17.9 (14.7 to 21.6) | 21.9 (18.3 to 25.7) |
| Flu A/Darwin/6/2021 H3N2, Day 31 | 75.3 (71.1 to 79.2) | 76.6 (72.3 to 80.5) |
| Flu A/Victoria/2570/2019 H1N1, Day 1 | 53.4 (48.9 to 57.8) | 61.0 (56.6 to 65.3) |
| Flu A/Victoria/2570/2019 H1N1, Day 31 | 92.3 (89.5 to 94.6) | 94.5 (92.0 to 96.5) |
| Flu B/Austria/1359417/2021 Victoria, Day 1 | 98.8 (97.4 to 99.6) | 99.6 (98.6 to 100.0) |
| Flu B/Austria/1359417/2021 Victoria, Day 31 | 100 (99.2 to 100) | 100 (99.2 to 100) |
| Flu B/Phuket/3073/2013 Yamagata, Day 1 | 96.8 (94.9 to 98.2) | 98.2 (96.6 to 99.2) |
| Flu B/Phuket/3073/2013 Yamagata, Day 31 | 100 (99.2 to 100) | 100 (99.2 to 100) |
MGI was defined as the geometric mean of the within-participant ratios of the post-dose titer over the pre-dose titer.
| Ratio | Co-Ad Group | Control Group |
|---|---|---|
| Flu A/Darwin/6/2021 H3N2 | 6.20 (5.49 to 7.00) | 5.87 (5.20 to 6.62) |
| Flu A/Victoria/2570/2019 H1N1 | 5.57 (4.81 to 6.46) | 4.53 (3.94 to 5.21) |
| Flu B/Austria/1359417/2021 Victoria | 2.92 (2.69 to 3.18) | 2.71 (2.51 to 2.93) |
| Flu B/Phuket/3073/2013 Yamagata | 3.13 (2.85 to 3.44) | 2.87 (2.62 to 3.14) |
The solicited administration site events after vaccination included erythema, pain and swelling.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Erythema, Flu administration at Day 1 | 4.0 (2.4 to 6.4) | 4.6 (2.8 to 7.1) |
| Erythema, RSV administration at Day 1 | 4.3 (2.5 to 6.6) | — |
| Erythema, RSV administration at Day 31 | — | 4.3 (2.5 to 6.7) |
| Pain, Flu administration at Day 1 | 47.0 (42.2 to 51.9) | 43.5 (37.7 to 47.4) |
| Pain, RSV administration at Day 1 | 55.6 (50.7 to 60.4) | — |
| Pain, RSV administration at Day 31 | — | 45.8 (40.8 to 50.8) |
| Swelling, Flu administration at Day 1 | 4.5 (2.7 to 6.9) | 5.6 (3.6 to 8.2) |
| Swelling, RSV administration at Day 1 | 4.0 (2.4 to 6.4) | — |
| Swelling, RSV administration at Day 31 | — | 4.3 (2.5 to 6.7) |
The solicited systemic events after vaccination include arthralgia, fatigue, fever, headache and myalgia.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Arthralgia, Dosing at Day 1 | 16.1 (12.7 to 19.9) | 13.8 (10.6 to 15.5) |
| Arthralgia, Dosing at Day 31 | — | 13.0 (9.9 to 16.7) |
| Fatigue, Dosing at Day 1 | 30.5 (26.1 to 35.1) | 22.0 (18.1 to 26.3) |
| Fatigue, Dosing at Day 31 | — | 23.5 (19.4 to 28.0) |
| Fever, Dosing at Day 1 | 2.1 (1.0 to 4.0) | 0.7 (0.1 to 2.1) |
| Fever, Dosing at Day 31 | — | 2.0 (0.9 to 3.9) |
| Headache, Dosing at Day 1 | 24.3 (20.3 to 28.7) | 17.1 (13.6 to 21.1) |
| Headache, Dosing at Day 31 | — | 19.0 (15.3 to 23.2) |
| Myalgia, Dosing at Day 1 | 40.2 (35.5 to 45.0) | 34.1 (29.5 to 38.8) |
| Myalgia, Dosing at Day 31 | — | 31.3 (26.7 to 36.0) |
An unsolicited AEs is an AE that is not included in a list of solicited events using a participant diary. Unsolicited events must have been spontaneously communicated by a participant who signs the informed consent. Unsolicited AEs include both serious, non-serious AEs and potential immune-mediated diseases (pIMDs).
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting Unsolicited Adverse Events (AEs) | 12.2 (9.5 to 15.3) | 13.5 (10.6 to 16.7) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events (SAEs) | 2.3 (1.2 to 4.0) | 2.9 (1.6 to 4.8) |
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. The investigator must exercise his/her medical/scientific judgment to determine whether other diseases have an autoimmune origin (i.e. pathophysiology involving systemic or organ-specific pathogenic autoantibodies) and should also be recorded as a pIMD.
| Percentage of participants | Co-Ad Group | Control Group |
|---|---|---|
| Percentage of Participants Reporting Potential Immune-mediated Disease (pIMDs) | 0 (0 to 0.7) | 0.4 (0.0 to 1.4) |
Collected over Solicited AEs were collected during 4-day follow-up period after each vaccination. Unsolicited AEs were collected during 30-day follow-up period after each vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to study end [6 months after last vaccination]).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Co-Ad Group | 1/516 (0.2%) | 12/516 (2.3%) | 339/516 (65.7%) |
| Control Group | 0/513 (0%) | 15/513 (2.9%) | 319/513 (62.2%) |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/516 | 1/513 |
| COVID-19Infections and infestations | 0/516 | 1/513 |
| Diverticulitis intestinal haemorrhagicInfections and infestations | 0/516 | 1/513 |
| GastroenteritisInfections and infestations | 0/516 | 1/513 |
| Pneumonia respiratory syncytial viralInfections and infestations | 0/516 | 1/513 |
| Spinal cord infectionInfections and infestations | 0/516 | 1/513 |
| Cardiac failure congestiveCardiac disorders | 1/516 | 1/513 |
| Angina unstableCardiac disorders | 0/516 | 1/513 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/516 | 1/513 |
| Sinus node dysfunctionCardiac disorders | 0/516 | 1/513 |
| Event | Co-Ad Group | Control Group |
|---|---|---|
| Injection site painGeneral disorders | 273/516 | 257/513 |
| MyalgiaMusculoskeletal and connective tissue disorders | 177/516 | 203/513 |
| FatigueGeneral disorders | 130/516 | 140/513 |
| HeadacheNervous system disorders | 113/516 | 128/513 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 73/516 | 91/513 |
| Injection site swellingGeneral disorders | 27/516 | 34/513 |
| Injection site erythemaGeneral disorders | 27/516 | 34/513 |
| PyrexiaGeneral disorders | 11/516 | 13/513 |
| COVID-19Infections and infestations | 2/516 | 10/513 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/516 | 7/513 |
| Age, Continuous(YEARS) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Mean | 71.3 ± 5.3 | 71.1 ± 5.1 | 71.2 ± 5.2 |
| Sex: Female, Male(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| Female | 267 | 243 | 510 |
| Male | 249 | 270 | 519 |
| Race/Ethnicity, Customized(Participants) | Co-Ad Group | Control Group | Total |
|---|---|---|---|
| American Indian or Alasaka Native | 4 | 6 | 10 |
| Asian | 4 | 4 | 8 |
| Black or African American | 72 | 68 | 140 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 355 | 352 | 707 |
| Other, Not Specified | 81 | 82 | 163 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Oct 2022 to primary completion in Mar 2023, 4 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 4 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →